Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-cash Items (2016 - 2020)

Myriad Genetics (MYGN) has disclosed Non-cash Items for 11 consecutive years, with $4.8 million as the latest value for Q1 2020.

  • On a quarterly basis, Non-cash Items changed N/A to $4.8 million in Q1 2020 year-over-year; TTM through Mar 2020 was $4.8 million, a N/A change, with the full-year FY2019 number at $5.5 million, changed N/A from a year prior.
  • Non-cash Items was $4.8 million for Q1 2020 at Myriad Genetics, down from $4.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $7.6 million in Q3 2016 to a low of $3.3 million in Q4 2016.
  • A 5-year average of $6.0 million and a median of $5.9 million in 2018 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 71.72% in 2016, then grew 11.94% in 2017.
  • Myriad Genetics' Non-cash Items stood at $3.3 million in 2016, then surged by 127.27% to $7.5 million in 2017, then fell by 25.33% to $5.6 million in 2018, then dropped by 12.5% to $4.9 million in 2019, then fell by 2.04% to $4.8 million in 2020.
  • Per Business Quant, the three most recent readings for MYGN's Non-cash Items are $4.8 million (Q1 2020), $4.9 million (Q4 2019), and $5.0 million (Q3 2019).